| Not Yet Recruiting | NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab NCT07261241 | New Approaches to Neuroblastoma Therapy Consortium | Phase 2 |
| Not Yet Recruiting | B7-H3.CD28Z.CART in Solid Tumors NCT07358260 | Robbie Majzner | Phase 1 |
| Not Yet Recruiting | Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Chil NCT07518654 | Michel Duval | Phase 1 |
| Recruiting | Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas NCT06465199 | Milton S. Hershey Medical Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neur NCT07111117 | Institut Curie | Phase 2 |
| Recruiting | Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors NCT06625190 | University of Florida | Phase 1 / Phase 2 |
| Recruiting | Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABR NCT07172958 | Children's National Research Institute | Phase 1 |
| Recruiting | An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma NCT07399821 | Princess Maxima Center for Pediatric Oncology | Phase 1 / Phase 2 |
| Recruiting | Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Rela NCT06995872 | National Cancer Institute (NCI) | Phase 1 |
| Not Yet Recruiting | Interest of Preoperative Arteriography to Identify the Adamkiewicz Artery Before Surgery for Basi-thoracic Neu NCT06798532 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation NCT06942039 | C17 Council | EARLY_Phase 1 |
| Not Yet Recruiting | GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuro NCT07090538 | Chinese PLA General Hospital | EARLY_Phase 1 |
| Recruiting | Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma NCT07067346 | Sichuan University | EARLY_Phase 1 |
| Recruiting | Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Rel NCT07027748 | Steven DuBois, MD | Phase 1 |
| Recruiting | Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma NCT06933394 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Not Yet Recruiting | A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children Wit NCT06948994 | Guangzhou Women and Children's Medical Center | Phase 1 / Phase 2 |
| Recruiting | Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma NCT06831552 | Dana-Farber Cancer Institute | N/A |
| Recruiting | 18F-mFBG PET Imaging in the Evaluation of Neuroblastoma NCT06852807 | First Affiliated Hospital of Zhejiang University | — |
| Recruiting | Fertility Preservation in Children With Solid Tumors: Detection of Residual Disease by a Sensitive Method NCT07141862 | University Hospital, Clermont-Ferrand | — |
| Not Yet Recruiting | Accurate Diagnosis and Grading of Pediatric Solid Tumors Based on Pathological Large Models NCT06822842 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Recruiting | Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma NCT06485947 | Princess Maxima Center for Pediatric Oncology | Phase 1 |
| Recruiting | Biomarkers of Resiliency In Childhood Cancer Surgery NCT06674811 | Mayo Clinic | — |
| Withdrawn | 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System NCT06233903 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | Phase 2 |
| Recruiting | Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis an NCT07195500 | Nanjing First Hospital, Nanjing Medical University | — |
| Recruiting | NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial NCT06450041 | New Approaches to Neuroblastoma Therapy Consortium | Phase 2 |
| Recruiting | Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma NCT06540963 | Giselle Sholler | Phase 2 |
| Recruiting | A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma NCT06684639 | The General Hospital of Western Theater Command | EARLY_Phase 1 |
| Recruiting | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations NCT06988475 | Cancer Research UK | Phase 2 / Phase 3 |
| Recruiting | Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neurob NCT06631391 | Sun Yat-sen University | Phase 1 |
| Recruiting | Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors NCT06541262 | Milton S. Hershey Medical Center | Phase 1 / Phase 2 |
| Withdrawn | PediCARE Health Equity Intervention in High-Risk Neuroblastoma NCT06335745 | Dana-Farber Cancer Institute | N/A |
| Recruiting | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or NCT06395103 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Withdrawn | Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma NCT06182410 | University of California, San Francisco | Phase 2 |
| Recruiting | N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastom NCT06528496 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Agnostic Therapy in Rare Solid Tumors NCT06638931 | Instituto do Cancer do Estado de São Paulo | Phase 2 |
| Recruiting | Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors NCT06500819 | Crystal Mackall, MD | Phase 1 |
| Not Yet Recruiting | Determining Patterns In Study Experiences of Neuroblastoma Patients NCT05918432 | Power Life Sciences Inc. | — |
| Recruiting | Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma NCT06818916 | Beijing Children's Hospital | N/A |
| Recruiting | Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma NCT06574698 | Guangzhou Women and Children's Medical Center | — |
| Recruiting | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly NCT06172296 | National Cancer Institute (NCI) | Phase 3 |
| Recruiting | Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma NCT05990751 | University College, London | Phase 1 |
| Recruiting | Identification of New Gene Spliceosomes in Neuroblastoma NCT06502210 | Affiliated Hospital of Nantong University | — |
| Recruiting | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Pos NCT05770037 | Cancer Research UK | Phase 2 / Phase 3 |
| Unknown | Dinutuximab Beta at the HUS and the Toulouse Oncopole NCT06275334 | University Hospital, Strasbourg, France | — |
| Recruiting | Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or R NCT05400603 | Emory University | Phase 1 |
| Recruiting | SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblas NCT05192980 | Institut Curie | N/A |
| Not Yet Recruiting | Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Mainten NCT06047535 | SciClone Pharmaceuticals | Phase 4 |
| Recruiting | A Study of Avutometinib for People With Solid Tumor Cancers NCT06104488 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification NCT06296732 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | — |
| Recruiting | A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma NCT06057948 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | MCT for the Harvard/UCSF ROBIN Center NCT06000787 | Brigham and Women's Hospital | N/A |
| Recruiting | Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma NCT06071897 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 3 |
| Recruiting | Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neurobl NCT06013618 | Sun Yat-Sen University Cancer Center | Phase 2 |
| Unknown | Use of Virtual Reality for Surgical Planning in Neuroblastoma NCT05781919 | Hospital Sant Joan de Deu | N/A |
| Recruiting | Engineering Immune Organoids to Study Pediatric Cancer NCT05890781 | Gustave Roussy, Cancer Campus, Grand Paris | N/A |
| Recruiting | A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-O NCT03966651 | Institut Claudius Regaud | Phase 1 |
| Unknown | Horse Therapy for Children, Adolescents and Young Adults in Remission From Medulloblastoma NCT05755295 | University Hospital, Toulouse | N/A |
| Recruiting | APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid NCT05701306 | Ascentage Pharma Group Inc. | Phase 1 |
| Terminated | Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in NCT05429502 | Novartis Pharmaceuticals | Phase 1 |
| Active Not Recruiting | Rapid Administration Pilot for Infusing Dinutuximab NCT05421897 | Children's Hospital Los Angeles | Phase 1 |
| Recruiting | Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma NCT05489887 | Giselle Sholler | Phase 2 |
| Not Yet Recruiting | Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma NCT05303727 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Recruiting | A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Sol NCT05135975 | Nationwide Children's Hospital | Phase 2 |
| Recruiting | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3 NCT04897321 | St. Jude Children's Research Hospital | Phase 1 |
| Recruiting | 18F-mFBG LAFOV PET/CT Compared to 123I-mIBG Scintigraphy SPECT/CT for Evaluation of Children With Neuroblastom NCT05826158 | Rigshospitalet, Denmark | N/A |
| Completed | Psychosocial Situation of Children With Rare Solid Abdominal Tumors and Their Families NCT05245123 | Universitätsklinikum Hamburg-Eppendorf | — |
| Completed | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors NCT05302921 | Children's National Research Institute | Phase 2 |
| Recruiting | Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma NCT07516678 | Sun Yat-sen University | — |
| Recruiting | 68Ga-DOTATATE Neuroblastoma Imaging Pilot NCT04559217 | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | Phase 2 |
| Withdrawn | Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of P NCT04909515 | Y-mAbs Therapeutics | Phase 2 |
| Unknown | Phase 1 Study of BCD-245 in Subjects With Neuroblastoma NCT05782959 | Biocad | Phase 1 |
| Active Not Recruiting | Open-Label Study of 18F-mFBG for Imaging Neuroblastoma NCT04724369 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | Phase 3 |
| Recruiting | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors NCT04851119 | Children's Oncology Group | Phase 1 / Phase 2 |
| Recruiting | Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Sol NCT04337177 | Valent Technologies, LLC | Phase 1 |
| Active Not Recruiting | PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy NCT04837547 | University of Florida | Phase 1 |
| Recruiting | 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor NCT05069220 | Peking Union Medical College Hospital | EARLY_Phase 1 |
| Recruiting | Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastom NCT05027386 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Recruiting | A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma NCT04936529 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Diagnostic Efficacy and Prognostic Value of 18F-FDG PET/CT (MR) in Pediatric Solid Blastoma NCT06190574 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Active Not Recruiting | A Study of N9 Chemotherapy in Children With Neuroblastoma NCT04947501 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Terminated | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and You NCT04730349 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Recruiting | 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma NCT04903899 | Jakob Stenman | Phase 2 |
| Unknown | Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 P NCT04864821 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | EARLY_Phase 1 |
| Terminated | Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib NCT04753658 | Pfizer | — |
| Recruiting | 18F-DOPA II - PET Imaging Optimization NCT04706910 | University of Alberta | Phase 3 |
| Unknown | Computer Aided Diagnostic Tool on Computed Tomography Images for Diagnosis of Retroperitoneal Tumor in Childre NCT05179850 | West China Hospital | — |
| Active Not Recruiting | Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozol NCT04385277 | Children's Oncology Group | Phase 2 |
| Unknown | 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma NCT04637503 | Shenzhen Geno-Immune Medical Institute | Phase 1 / Phase 2 |
| Recruiting | Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma NCT04301843 | Giselle Sholler | Phase 2 |
| Completed | Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!") NCT04474678 | Medical University of Vienna | N/A |
| Terminated | 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapse NCT04023331 | Clarity Pharmaceuticals Ltd | Phase 1 / Phase 2 |
| Completed | Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma NCT06851221 | Meyer Children's Hospital IRCCS | N/A |
| Active Not Recruiting | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults NCT04483778 | Seattle Children's Hospital | Phase 1 |
| Active Not Recruiting | A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma NCT04106219 | Eli Lilly and Company | Phase 1 |
| Terminated | 9-ING-41 in Pediatric Patients With Refractory Malignancies. NCT04239092 | Actuate Therapeutics Inc. | Phase 1 |
| Terminated | GVAX Plus Checkpoint Blockade in Neuroblastoma NCT04239040 | Dana-Farber Cancer Institute | Phase 1 |
| Terminated | A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combi NCT04029688 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Unknown | Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging NCT04017104 | British Columbia Cancer Agency | — |
| Unknown | A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma NCT03561259 | Jubilant DraxImage Inc. | Phase 2 |
| Recruiting | A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuxim NCT04253015 | RECORDATI GROUP | — |
| Active Not Recruiting | An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors NCT04040088 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults NCT03618381 | Seattle Children's Hospital | Phase 1 |
| Active Not Recruiting | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors NCT03709680 | Pfizer | Phase 2 |
| Active Not Recruiting | 18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma NCT03541720 | St. Jude Children's Research Hospital | EARLY_Phase 1 |
| Active Not Recruiting | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and NCT03478462 | Cellectar Biosciences, Inc. | Phase 1 |
| Terminated | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/R NCT03860207 | Y-mAbs Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/ NCT03721068 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells NCT02573896 | New Approaches to Neuroblastoma Therapy Consortium | Phase 1 |
| Terminated | 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases NCT03275402 | Y-mAbs Therapeutics | Phase 2 / Phase 3 |
| Completed | Pediatric Solid Tumor Metabolism [A Prospective Study Exploring Metabolism of Solid Tumors in Pediatrics] NCT03686566 | University of Texas Southwestern Medical Center | — |
| Completed | MIBG With Dinutuximab +/- Vorinostat NCT03332667 | New Approaches to Neuroblastoma Therapy Consortium | Phase 1 |
| Completed | Nutritional Status in Neuroblastoma in Sao Paolo, Brazil NCT03517280 | Columbia University | — |
| Active Not Recruiting | DOTATOC PET/CT for Imaging NET Patients NCT03583528 | British Columbia Cancer Agency | — |
| Active Not Recruiting | Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refr NCT02914405 | University Hospital Southampton NHS Foundation Trust | Phase 1 |
| Recruiting | Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (N NCT03126916 | Children's Oncology Group | Phase 3 |
| Unknown | Investigating the Microbiome and Volatile Organic Compound Profile of Children With Neuroblastoma NCT03545542 | Medical University of Graz | N/A |
| Terminated | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients NCT03458728 | Bayer | Phase 1 / Phase 2 |
| Active Not Recruiting | Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) NCT03496402 | Institut Curie | N/A |
| Completed | Oral Liquid 13-cis-retinoic Acid (13-CRA) NCT03291080 | Nova Laboratories Limited | Phase 1 / Phase 2 |
| Recruiting | Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salva NCT03363373 | Y-mAbs Therapeutics | Phase 2 |
| Withdrawn | Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and H NCT03209869 | University of Wisconsin, Madison | Phase 1 |
| Recruiting | GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma NCT03294954 | Baylor College of Medicine | Phase 1 |
| Active Not Recruiting | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or O NCT03373097 | Bambino Gesù Hospital and Research Institute | Phase 1 / Phase 2 |
| Completed | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed o NCT03236857 | AbbVie | Phase 1 |
| Completed | Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) NCT03273712 | University of Iowa | Phase 2 |
| Completed | NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) NCT03107988 | New Approaches to Neuroblastoma Therapy Consortium | Phase 1 |
| Withdrawn | 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBL NCT02439788 | Baylor College of Medicine | Phase 1 |
| Completed | 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety NCT03042416 | University of Alberta | Phase 3 |
| Active Not Recruiting | Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma NCT03503864 | Yang Li | Phase 2 |
| Recruiting | Familial Investigations of Childhood Cancer Predisposition NCT03050268 | St. Jude Children's Research Hospital | — |
| Recruiting | Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies NCT04308330 | New York Medical College | Phase 1 |
| Completed | A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-R NCT03033303 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Withdrawn | Dosimetry Guided PRRT With 90Y-DOTATOC NCT03013387 | Sue O'Dorisio | Phase 2 |
| Recruiting | International PPB/DICER1 Registry NCT03382158 | Children's Hospitals and Clinics of Minnesota | — |
| Withdrawn | HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Soli NCT02557854 | Theodore Laetsch | Phase 1 |
| Completed | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors NCT02982941 | MacroGenics | Phase 1 |
| Completed | Racotumomab in Patients With High-risk Neuroblastoma NCT02998983 | Laboratorio Elea Phoenix S.A. | Phase 2 |
| Terminated | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumor NCT02536183 | AeRang Kim | Phase 1 |
| Completed | Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lympho NCT02909777 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Pati NCT02924324 | Memorial Sloan Kettering Cancer Center | N/A |
| Unknown | G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tum NCT02933333 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Phase 4 |
| Active Not Recruiting | Neuroblastoma Precision Trial NCT02868268 | New Approaches to Neuroblastoma Therapy Consortium | — |
| Terminated | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) NCT02624388 | University of Virginia | Phase 2 |
| Terminated | Next Generation Personalized Neuroblastoma Therapy NCT02780128 | Yael P Mosse | Phase 1 |
| Completed | High-Risk Neuroblastoma Chemotherapy Without G-CSF NCT02786719 | Baylor College of Medicine | N/A |
| Recruiting | Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neurobla NCT02605421 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Withdrawn | A Combined Cell Therapy Approach to the Treatment of Neuroblastoma NCT02745756 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Terminated | Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients NCT02693171 | United Therapeutics | — |
| Recruiting | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and S NCT02508038 | University of Wisconsin, Madison | Phase 1 |
| Recruiting | Neuroblastoma Maintenance Therapy Trial NCT02679144 | Giselle Sholler | Phase 2 |
| Completed | Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma NCT02650648 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma NCT02765243 | Zhujiang Hospital | Phase 1 |
| Unknown | Impact of Image-defined Risk Factors on the Outcome of Patients With Neuroblastoma: A Retrospective Study NCT02558244 | Assiut University | — |
| Terminated | Trial of Tolcapone With Oxaliplatin for Neuroblastoma NCT02630043 | Giselle Sholler | Phase 1 |
| Unknown | Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma NCT02615106 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Phase 2 |
| Terminated | NB2013-HR German (GPOH) / Dutch (DCOG) Trial NCT02641782 | University of Cologne | Phase 2 |
| Active Not Recruiting | Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma NCT02298348 | New Approaches to Neuroblastoma Therapy Consortium | Phase 1 |
| Completed | Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors NCT02441062 | Sue O'Dorisio | Phase 2 |
| Recruiting | Pediatric Precision Laboratory Advanced Neuroblastoma Therapy NCT02559778 | Giselle Sholler | Phase 2 |
| Terminated | SF1126 for Patients With Relapsed or Refractory Neuroblastoma NCT02337309 | New Approaches to Neuroblastoma Therapy Consortium | Phase 1 |
| Unknown | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Mali NCT02457650 | Shenzhen Second People's Hospital | Phase 1 |
| Unknown | Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or R NCT02743429 | University Medicine Greifswald | Phase 2 |
| Completed | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remis NCT02395666 | Giselle Sholler | Phase 2 |
| Completed | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors NCT02390843 | Emory University | Phase 1 |
| Terminated | ODSH + ICE Chemotherapy in Pediatric Solid Tumors NCT02164097 | New York Medical College | Phase 1 |
| Completed | Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma NCT02169609 | Fundació Sant Joan de Déu | Phase 2 |
| Active Not Recruiting | Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 NCT02311621 | Seattle Children's Hospital | Phase 1 |
| Active Not Recruiting | PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study NCT02307630 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected NCT02130869 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma NCT02245997 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neurobla NCT02176967 | Children's Oncology Group | Phase 3 |
| Completed | Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody NCT02159443 | St. Jude Children's Research Hospital | — |
| Completed | Molecular-Guided Therapy for Childhood Cancer NCT02162732 | Giselle Sholler | N/A |
| Completed | 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat NCT02035137 | New Approaches to Neuroblastoma Therapy Consortium | Phase 2 |
| Terminated | GA-68 DOTA-TOC of Somatostatin Positive Malignancies NCT02177773 | University of California, San Francisco | Phase 1 / Phase 2 |
| Recruiting | Phase II Study of Proton Radiation Therapy for Neuroblastoma NCT02112617 | Massachusetts General Hospital | N/A |
| Terminated | Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma NCT02163356 | South Plains Oncology Consortium | Phase 1 |
| Completed | MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors NCT02076906 | AeRang Kim | Phase 1 |
| Active Not Recruiting | iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma NCT01953900 | Baylor College of Medicine | Phase 1 |
| Completed | A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard NCT01288573 | Genzyme, a Sanofi Company | Phase 1 / Phase 2 |
| Completed | Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma NCT02100930 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With NCT02107963 | National Cancer Institute (NCI) | Phase 1 |
| Completed | N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan NCT02030964 | New Approaches to Neuroblastoma Therapy Consortium | Phase 1 |
| Completed | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With NCT01962103 | Celgene | Phase 1 / Phase 2 |
| Unknown | Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophos NCT02013336 | South Plains Oncology Consortium | Phase 1 |
| Active Not Recruiting | 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN NCT01822652 | Baylor College of Medicine | Phase 1 |
| Terminated | Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With NCT01987596 | Barbara Ann Karmanos Cancer Institute | Phase 3 |
| Unknown | A Pilot Study on ALK Gene Mutations in Neuroblastoma NCT01986595 | National Taiwan University Hospital | — |
| Withdrawn | Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma NCT01916187 | NCIC Clinical Trials Group | Phase 1 |
| Completed | Therapy for Children With Advanced Stage Neuroblastoma NCT01857934 | St. Jude Children's Research Hospital | Phase 2 |
| Active Not Recruiting | Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children NCT02308527 | University of Birmingham | Phase 2 |
| Completed | NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors NCT01875601 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma NCT01747876 | Novartis Pharmaceuticals | Phase 1 |
| Unknown | Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors NCT01807468 | Samsung Medical Center | Phase 2 |
| Completed | Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos NCT01868269 | Institut Curie | Phase 3 |
| Terminated | 124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A NCT01583842 | Miguel Pampaloni | EARLY_Phase 1 |
| Completed | Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT NCT01869725 | Sue O'Dorisio | Phase 2 |
| Terminated | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors NCT02100891 | Monica Thakar | Phase 2 |
| Completed | Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer NCT01802567 | Giselle Sholler | N/A |
| Completed | A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma NCT01802138 | Seoul National University Hospital | N/A |
| Active Not Recruiting | Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patie NCT01757626 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma NCT01460901 | Children's Mercy Hospital Kansas City | Phase 1 |
| Completed | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory S NCT01625351 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neurobla NCT01662804 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | iCAT for Recurrent/Refractory/HR Solid Tumors NCT01853345 | Dana-Farber Cancer Institute | — |
| Completed | ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma NCT01592045 | United Therapeutics | Phase 1 / Phase 2 |
| Completed | Study of MLN8237 in Combination With Irinotecan and Temozolomide NCT01601535 | New Approaches to Neuroblastoma Therapy Consortium | Phase 1 / Phase 2 |
| Completed | Studying Chromosomes in Samples From Younger Patients With Neuroblastoma NCT01589341 | Children's Oncology Group | — |
| Completed | Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurr NCT01576692 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | High Dose Chemotherapy and Autologous Transplant for Neuroblastoma NCT01526603 | Masonic Cancer Center, University of Minnesota | N/A |
| Completed | Studying Gene Expression in Samples From Younger Patients With Neuroblastoma NCT01553448 | Children's Oncology Group | — |
| Completed | Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors NCT01619865 | Sue O'Dorisio | Phase 1 / Phase 2 |
| Completed | Studying Biomarkers in Samples From Patients With High-Risk Neuroblastoma NCT01510600 | Children's Oncology Group | — |
| Completed | Gene Expression in Predicting Outcome in Samples From Patients With High-Risk Neuroblastoma NCT01520233 | Children's Oncology Group | — |
| Unknown | Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2) NCT01701479 | St. Anna Kinderkrebsforschung | Phase 1 / Phase 2 |
| Terminated | Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma NCT01483820 | Giselle Sholler | Phase 1 / Phase 2 |
| Completed | Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma NCT01493830 | Children's Oncology Group | — |
| Terminated | Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma NCT01505608 | Giselle Sholler | Phase 1 / Phase 2 |
| Completed | Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Ne NCT01492673 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors NCT01518413 | HMeany | Phase 1 |
| Completed | Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging NCT01482741 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Allogeneic Stem Cell Transplantation for Advanced Neuroblastoma Using MHC Mismatched Related Donors NCT01462396 | Children's Mercy Hospital Kansas City | Phase 1 |
| Unknown | Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children W NCT01156350 | University Hospital, Clermont-Ferrand | Phase 2 |
| Completed | Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors NCT01419834 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Terminated | Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma NCT01404702 | University of Alabama at Birmingham | Phase 1 |
| Recruiting | Neuroblastoma Biology Study NCT01587300 | New Approaches to Neuroblastoma Therapy Consortium | — |
| Completed | Protein Expression in Human Neuroblastoma Tumor Samples NCT01407731 | Children's Oncology Group | — |
| Withdrawn | New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma NCT01174537 | Hadassah Medical Organization | Phase 1 / Phase 2 |
| Completed | Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma NCT01387724 | Children's Oncology Group | — |
| Completed | Gene Mutation in Samples From Young Patients With Pleuropulmonary Blastoma Syndrome at Risk for Developing Can NCT01353300 | Children's Oncology Group | — |
| Completed | Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma NCT01355679 | Giselle Sholler | N/A |
| Completed | Biomarkers in Samples From Young Patients With Neuroblastoma NCT01358604 | Children's Oncology Group | — |
| Unknown | Immunomonitoring of Children With Neuroblastoma NCT01295762 | Centre Leon Berard | N/A |
| Completed | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors NCT01331135 | Emory University | Phase 1 |
| Completed | High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuro NCT01313936 | University of California, San Francisco | Phase 1 |
| Withdrawn | Aflac ST1001 Prolonged Isotretinoin NCT01319838 | Emory University | Phase 1 |
| Unknown | Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission NCT01308905 | Barbara Ann Karmanos Cancer Institute | N/A |
| Completed | Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides NCT01598454 | Laboratorio Elea Phoenix S.A. | Phase 1 |
| Completed | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminar NCT01125800 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Active Not Recruiting | Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma NCT01192555 | Baylor College of Medicine | Phase 1 / Phase 2 |
| Completed | To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory C NCT01222780 | Acrotech Biopharma Inc. | Phase 1 |
| Completed | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablativ NCT01183429 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow NCT01183897 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients NCT01169584 | Jennerex Biotherapeutics | Phase 1 |
| Terminated | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Ri NCT01183884 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma NCT01241162 | University of Louisville | Phase 1 |
| Completed | High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloa NCT01183416 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Biomarkers in Young Patients With Neuroblastoma NCT01169376 | Children's Oncology Group | — |
| Withdrawn | A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors NCT01130623 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including NCT01132911 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Pharmacokinetic Study of Doxorubicin in Children With Cancer NCT01095926 | University Hospital Muenster | Phase 2 |
| Completed | Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma NCT01114555 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related NCT01109394 | National Cancer Institute (NCI) | — |
| Completed | HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors NCT00931931 | Timothy Cripe | Phase 1 |
| Terminated | Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Canc NCT00946283 | Rutgers, The State University of New Jersey | N/A |
| Completed | N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma NCT01019850 | New Approaches to Neuroblastoma Therapy Consortium | Phase 1 |
| Completed | Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide NCT01059071 | Giselle Sholler | Phase 1 |
| Terminated | Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant NCT01077440 | Vanderbilt University | — |
| Completed | Exploring the Possibility to Use Glycosyltransferase as a Prognosis Marker of Neuroblastoma NCT01638572 | National Taiwan University Hospital | — |
| Withdrawn | Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma NCT00992173 | Molecular Insight Pharmaceuticals, Inc. | Phase 2 |
| Completed | N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuro NCT00885326 | New Approaches to Neuroblastoma Therapy Consortium | Phase 1 |
| Terminated | A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Par NCT00960063 | Merck Sharp & Dohme LLC | Phase 1 |
| Terminated | Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft T NCT01204450 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Recruiting | Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms NCT01005654 | National Cancer Institute (NCI) | — |
| Active Not Recruiting | Genomic Structural Variation in Cancer Susceptibility NCT00996710 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblast NCT01048892 | Children's Oncology Group | Phase 1 |
| Unknown | Nurse Case Manager Model on Neuroblastoma Caregiver's Uncertainty NCT01525251 | National Taiwan University Hospital | — |
| Active Not Recruiting | Methionine PET/CT Studies In Patients With Cancer NCT00840047 | St. Jude Children's Research Hospital | Phase 2 |
| Withdrawn | 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) NCT01048086 | University of Iowa | Phase 2 |
| Completed | Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours NCT00918320 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Withdrawn | A Vaccine Study for High Risk Cancers NCT00944580 | Penn State University | Phase 1 |
| Active Not Recruiting | Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-gluca NCT00911560 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Enrolling By Invitation | The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells NCT01868490 | Siriraj Hospital | Phase 1 / Phase 2 |
| Completed | Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma NCT00877110 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma NCT00867568 | Giselle Sholler | Phase 1 |
| Terminated | A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors NCT00947167 | Pamela L. Kunz | Phase 2 |
| Completed | Genetic Susceptibility Biomarkers in Children With Neuroblastoma (Also Known as Neuroblastoma Epidemiology in NCT01119560 | Children's Oncology Group | — |
| Unknown | Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma NCT00939965 | Children's Cancer and Leukaemia Group | N/A |
| Completed | Informed Consent in Pediatric Cancer Trials NCT00923650 | National Cancer Institute (NCI) | — |
| Terminated | Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma NCT00808899 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Studying Tumor Samples From Young Patients With Neuroblastoma NCT00907920 | Children's Oncology Group | — |
| Completed | Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblas NCT00960739 | Centre Oscar Lambret | Phase 2 |
| Completed | A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcom NCT00743496 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for t NCT02864563 | Institut Curie | N/A |
| Terminated | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Mali NCT00788125 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Unknown | 131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-r NCT00798148 | Tehran University of Medical Sciences | Phase 1 / Phase 2 |
| Withdrawn | Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL. NCT00874315 | Nationwide Children's Hospital | Phase 2 |
| Completed | Reduced Intensity Stem Cell Transplantation in Children With Relapsed Neuroblastoma After Autologous Transplan NCT00793351 | Samsung Medical Center | Phase 2 |
| Completed | MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors NCT02444884 | Children's Oncology Group | Phase 1 |
| Completed | The Role of Aromatic Hydrocarbon Receptor in the Tumorigenesis of Neuroblastoma and Its Relationship With MYCN NCT01075360 | National Taiwan University Hospital | — |
| Terminated | Blood Samples From Patients on a Clinical Trial to CINV During HSCT NCT00900068 | OHSU Knight Cancer Institute | — |
| Completed | Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma NCT00793845 | Samsung Medical Center | Phase 2 |
| Completed | A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Childre NCT00754286 | Albert Einstein College of Medicine | N/A |
| Withdrawn | High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating You NCT00389766 | Children's Cancer and Leukaemia Group | Phase 2 |
| Completed | Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ C NCT00716976 | Children's Oncology Group | Phase 3 |
| Terminated | Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transpla NCT00813501 | City of Hope Medical Center | — |
| Completed | A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transp NCT00782145 | Tufts Medical Center | Phase 3 |
| Completed | N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma NCT00659984 | Molecular Insight Pharmaceuticals, Inc. | Phase 2 |
| Completed | A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells NCT00703222 | Baylor College of Medicine | Phase 1 / Phase 2 |
| Terminated | Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma NCT00698009 | M.D. Anderson Cancer Center | Phase 2 |